Buenos Aires, Argentina – Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), in-house developed by Shanghai MicroPort Medical (Group) Co (MicroPort®), was approved for market launch by the ANMAT, Argentina's National Administration of Drugs, Foods and Medical Devices, in July.
Firehawk® is MicroPort®'s new generation stent designed for the treatment of coronary artery stenosis and occlusion, following Firebird® Rapamycin-Eluting Coronary Stent and Firebird2® Rapamycin-Eluting Coronary CoCr Stent. It is the world's first and only target eluting stent ("TES"). As the world's lowest drug dosage stent, Firehawk® adopts TARGET Eluting Technique to achieve free redundancy. Firehawk® combines the merits of bare metal stents and drug-eluting stents, and can lower the incidence of long-term stent thrombosis and in-stent restenosis.
Coronary heart disease is one of the major diseases in Latin America. Currently, Argentina ranked No.2 in the market of Latin America in terms of the amount of PCI (Percutaneous Coronary Intervention) surgical operations. As Firehawk® is permitted for market launch in Argentina, it will provide a more ideal solution for local patients with coronary heart disease.
Firehawk® received the registration certificate from China Food and Drug Administration and the CE Mark approval from the European Notified Body, and was approved for market launch in several overseas countries including Thailand, the Philippines, Indonesia, Peru, Brazil and India.